lead position
Sponsored content
Sponsored by
Maiwald
Features list
-
China’s National IP Strategy has its share of critics, especially when it comes to incentives for patent filings. Xianjie Ding and Di Yao argue, however, that despite legitimate concerns about a patent bubble, there is also significant progress being made
-
A growing number of companies are using bilateral investment treaties to fight for their IP rights. Viren Mascarenhas and Giulia Previti explain how
-
The UK Supreme Court has ruled that the EPO’s decision to amend a patent has retrospective effect, rescuing a defendant from potentially large damages. Huw Evans and Seiko Hidaka explain the significance of the ruling
-
China’s National IP Strategy is now in its sixth year. Thomas Pattloch, former EU IP officer in Beijing, examines its effect on China’s IP system from an international perspective
-
Alejandro Luna of Olivares & Cía advises Mexico’s R&D pharmaceutical association AMIIF. In July he attended the Trans-Pacific Partnership (TPP) talks in Kota Kinabalu, Malaysia on its behalf. He tells Emma Barraclough about the experience
-
Declan Hamill, chief of staff and vice president (legal affairs) for Rx&D tells James Nurton why the innovative life sciences industry has concerns about the lack of patent term restoration, utility standards and access to medicines
Local Insights